Overview

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary purposes of the study are to evaluate the effectiveness of Ingaron in the complex therapy of chronic prostatitis, to assess the safety of using Ingaron in patients with chronic prostatitis.
Phase:
Phase 3
Details
Lead Sponsor:
SPP Pharmaclon Ltd.
Treatments:
Interferon-gamma
Interferons